Genetic Signatures Limited

GSS

AU000000GSS4

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 08:55:59 14/01/2026 +04			5-day change	1st Jan Change
0.2250 ^AUD	-2.17%		-6.25%	-10.00%

12-15	Genetic Signatures CEO to Step Down, Shares Fall 9%	MT
12-15	Genetic Signatures says CEO Allison Rossiter to leave	RE

Genetic Signatures says CEO Allison Rossiter to leave

Published on 12/15/2025 at 05:28 am +04

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Genetic Signatures Limited

12-15	Genetic Signatures CEO to Step Down, Shares Fall 9%	MT
12-15	Genetic Signatures says CEO Allison Rossiter to leave	RE
11-17	Genetic Signatures Limited Receives $4.4 Million R&D Tax Incentive	CI
11-11	Genetic Signatures Chief Financial, Operating Officer Resigns	MT
11-11	Genetic Signatures announces resignation of CFO Karl Pechmann	RE
11-11	Genetic Signatures Limited Announces Resignation of Karl Pechmann as Chief Financial Officer, Effective 30 January 2026	CI
11-11	Genetic Signatures Limited Announces Resignation of Karl Pechmann as Chief Operating Officer and Joint Company Secretary, Effective 30 January 2026	CI
11-07	Genetic Signatures Updates CEO Remuneration	MT
21/10/25	Genetic Signatures says quarterly sales reach A$5.4 million	RE
25/08/25	Genetic Signatures Limited, 2025 Earnings Call, Aug 25, 2025
25/08/25	Genetic Signatures posts loss for year attributable a$20.1 million	RE
25/08/25	Genetic Signatures Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
18/08/25	Genetic Signatures Limited Announces Appointment of Dr Susanne Pedersen as Chief Technology Officer	CI
18/08/25	Genetic Signatures Appoints Chief Technology Officer	MT
22/07/25	Genetic Signatures announces strategic partnership with Tecan and Repado	RE
22/07/25	Genetic Signatures reports quarterly sales of A$4.4 million	RE
26/02/25	Genetic Signatures Logs Loss For Half-Year Attributable A$15.2 Mln	RE
26/02/25	Genetic Signatures Limited, H1 2025 Earnings Call, Feb 26, 2025
26/02/25	Genetic Signatures Limited Reports Earnings Results for the Half Year Ended December 31, 2024	CI
01/10/24	Genetic Signatures Limited Appoints Jenny Harry as Director, Effective from 1 October 2024	CI
01/10/24	Genetic Signatures Limited Appoints Anne Lockwood as Director, Effective from 1 October 2024	CI
30/08/24	Genetic Signatures Limited Reports Earnings Results for the Full Year Ended June 30, 2024	CI
22/08/24	Genetic Signatures Limited Announces Changes to Board of Directors	CI
04/06/24	Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen? Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US	CI
04/06/24	Genetic Signatures Launches AU$30 Million Equity Raising	MT

Chart Genetic Signatures Limited

Duration

Period

GSS: Dynamic Chart

Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company's principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit, and others.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

03-04 - Q2 2026 Earnings Release (Projected)

More about the company